Antitumor effect of chondroitin AC lyase (PsPL8A) from Pedobacter saltans on melanoma and fibrosarcoma cell lines by in vitro analysis

2019 ◽  
Vol 71 (1) ◽  
pp. 167-174
Author(s):  
Aruna Rani ◽  
Vikky Rajulapati ◽  
Arun Goyal
Keyword(s):  
Cell Lines ◽  
Antitumor Effect ◽  
Fibrosarcoma Cell ◽  
Chondroitin Ac Lyase ◽  
Vitro Analysis ◽  
In Vitro Analysis

Immunophenotype of Mammary Tumour Cell Lines for In-Vitro Analysis Using Three Different Techniques

2020 ◽  
Vol 174 ◽  
pp. 184
Author(s):  
F. Torrigiani ◽  
A. Sammarco ◽  
M.E. Gelain ◽  
F. Bonsembiante ◽  
R. Zanetti ◽  
...  
Keyword(s):  
Cell Lines ◽  
Tumour Cell ◽  
Mammary Tumour ◽  
Tumour Cell Lines ◽  
Vitro Analysis ◽  
In Vitro Analysis

scholarly journals PD-L1 Is an Independent Prognostic Marker in Middle Eastern PTC and Its Expression Is Upregulated by BRAFV600E Mutation

Cancers ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 555
Author(s):  
Abdul K. Siraj ◽  
Sandeep Kumar Parvathareddy ◽  
Poyil Pratheeshkumar ◽  
Sasidharan Padmaja Divya ◽  
Saif S. Al-Sobhi ◽  
...  
Keyword(s):  
Cell Growth ◽  
Prognostic Marker ◽  
Cell Lines ◽  
Braf Mutation ◽  
Middle Eastern ◽  
Disease Free Survival ◽  
Over Expression ◽  
Vitro Analysis ◽  
In Vitro Analysis

PD-L1 inhibition is a promising therapeutic target whose efficacy has been demonstrated in several cancers. Immunohistochemistry was performed to assess PD-L1 protein expression in PTC. We further conducted in vitro analysis to investigate the role of PD-L1 in regulating BRAFV600E in PTC cell lines. PD-L1 over-expression was noted in 32.4% (473/1458) of cases and significantly associated with aggressive clinico-pathological parameters. Importantly, PD-L1 was found to be an independent poorer prognostic marker. We also found PD-L1 to be significantly associated with BRAF mutation and patients with co-existing PD-L1 over-expression and BRAF mutation had a poor disease-free survival compared to patients with BRAF mutation alone. In vitro analysis showed high expression of PD-L1 in BRAF-mutated PTC cell lines compared to a BRAF wild-type cell line. Inhibition of BRAF using vemurafenib induced PD-L1 expression in BRAF-mutated cell lines without affecting cell growth. Knockdown of PD-L1 in BRAF-mutated cell lines significantly decreased the cell growth and induced apoptosis. Our data suggest that PD-L1 might represent a useful prognostic marker in Middle Eastern PTC and PD-L1 inhibition could be a potential therapeutic option for aggressive PTC cancers, such as the tall cell variant, BRAF mutation-positive patients that are unresponsive to standard treatment.

Sign in / Sign up

Export Citation Format

Share Document